What role does drug development investment play in lurbinectedin's cost?

Drug development investment plays a big role in lurbinectedin’s cost because it ultimately feeds into how companies price the medicine to recoup huge R&D expenses and to fund ongoing work. Concretely:

• Recouping R&D spend: Lurbinectedin’s price needs to cover costs from early discovery through clinical trials (often many thousands of patient-years), regulatory submissions, and approval delays/failures.
• Cost of capital and risk: Investment money is costly and the chance of failure in oncology drug development is high—so pricing typically builds in a risk premium.
• Manufacturing and scale-up investments: Developing a workable, reliable manufacturing process (GMP manufacturing, quality systems, supply chain) also adds significant upfront costs that must be recovered through sales.
• Market access and commercialization costs: Investments in clinical evidence generation, post-marketing requirements, and payer/HTA negotiations affect pricing strategies.
• Limited competition (at least initially): During patent/exclusivity periods, there are fewer pricing constraints, so pricing can reflect the need to recover development investment.

If you want, tell me which country/price context you mean (e.g., U.S. wholesale acquisition cost vs. NHS procurement vs. out-of-pocket), and I can explain how development investment interacts with regulatory exclusivity, payers, and distribution margins in that specific setting.